iBio (IBIO) Competitors

iBio logo
$0.71 -0.03 (-3.42%)
Closing price 04:00 PM Eastern
Extended Trading
$0.70 -0.01 (-0.81%)
As of 07:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IBIO vs. CGEN, ADCT, UPB, MDWD, and KROS

Should you buy iBio stock or one of its competitors? iBio's main competitors and comparable companies include Compugen (CGEN), ADC Therapeutics (ADCT), Upstream Bio (UPB), MediWound (MDWD), and Keros Therapeutics (KROS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does iBio compare to Compugen?

Compugen (NASDAQ:CGEN) and iBio (NASDAQ:IBIO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends.

Compugen has a net margin of 47.90% compared to iBio's net margin of 0.00%. Compugen's return on equity of 39.30% beat iBio's return on equity.

Company Net Margins Return on Equity Return on Assets
Compugen47.90% 39.30% 25.51%
iBio N/A -40.05%-35.35%

Compugen presently has a consensus price target of $5.00, suggesting a potential upside of 145.10%. iBio has a consensus price target of $6.00, suggesting a potential upside of 749.02%. Given iBio's higher possible upside, analysts clearly believe iBio is more favorable than Compugen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Compugen
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.00
iBio
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
2 Strong Buy rating(s)
3.00

12.2% of Compugen shares are held by institutional investors. Comparatively, 7.9% of iBio shares are held by institutional investors. 9.5% of Compugen shares are held by company insiders. Comparatively, 1.6% of iBio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Compugen has higher revenue and earnings than iBio. iBio is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Compugen$75.93M2.54$35.34M$0.395.23
iBio$100K497.94-$33.04M-$0.28N/A

In the previous week, iBio had 4 more articles in the media than Compugen. MarketBeat recorded 15 mentions for iBio and 11 mentions for Compugen. Compugen's average media sentiment score of 0.66 beat iBio's score of 0.66 indicating that Compugen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Compugen
2 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
iBio
2 Very Positive mention(s)
3 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Compugen has a beta of 2.85, indicating that its share price is 185% more volatile than the broader market. Comparatively, iBio has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market.

Summary

Compugen beats iBio on 11 of the 16 factors compared between the two stocks.

How does iBio compare to ADC Therapeutics?

ADC Therapeutics (NYSE:ADCT) and iBio (NASDAQ:IBIO) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

In the previous week, iBio had 6 more articles in the media than ADC Therapeutics. MarketBeat recorded 13 mentions for iBio and 7 mentions for ADC Therapeutics. iBio's average media sentiment score of 0.66 beat ADC Therapeutics' score of 0.42 indicating that iBio is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ADC Therapeutics
0 Very Positive mention(s)
4 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
iBio
1 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

iBio has a net margin of 0.00% compared to ADC Therapeutics' net margin of -95.73%. ADC Therapeutics' return on equity of 0.00% beat iBio's return on equity.

Company Net Margins Return on Equity Return on Assets
ADC Therapeutics-95.73% N/A -28.26%
iBio N/A -40.05%-35.35%

ADC Therapeutics presently has a consensus target price of $5.00, indicating a potential upside of 271.75%. iBio has a consensus target price of $6.00, indicating a potential upside of 720.01%. Given iBio's stronger consensus rating and higher possible upside, analysts clearly believe iBio is more favorable than ADC Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ADC Therapeutics
1 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.33
iBio
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
2 Strong Buy rating(s)
3.00

iBio has lower revenue, but higher earnings than ADC Therapeutics. iBio is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ADC Therapeutics$84.87M2.23-$142.62M-$0.52N/A
iBio$100K515.56-$33.04M-$0.28N/A

ADC Therapeutics has a beta of 1.82, suggesting that its stock price is 82% more volatile than the broader market. Comparatively, iBio has a beta of 1.48, suggesting that its stock price is 48% more volatile than the broader market.

41.1% of ADC Therapeutics shares are held by institutional investors. Comparatively, 7.9% of iBio shares are held by institutional investors. 5.1% of ADC Therapeutics shares are held by insiders. Comparatively, 1.6% of iBio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

iBio beats ADC Therapeutics on 10 of the 17 factors compared between the two stocks.

How does iBio compare to Upstream Bio?

iBio (NASDAQ:IBIO) and Upstream Bio (NASDAQ:UPB) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends.

iBio has higher earnings, but lower revenue than Upstream Bio. iBio is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
iBio$100K497.94-$33.04M-$0.28N/A
Upstream Bio$2.87M41.06-$143.44M-$3.02N/A

iBio currently has a consensus price target of $6.00, indicating a potential upside of 749.02%. Upstream Bio has a consensus price target of $26.67, indicating a potential upside of 1,140.31%. Given Upstream Bio's higher possible upside, analysts plainly believe Upstream Bio is more favorable than iBio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
iBio
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
2 Strong Buy rating(s)
3.00
Upstream Bio
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43

7.9% of iBio shares are held by institutional investors. 1.6% of iBio shares are held by company insiders. Comparatively, 16.5% of Upstream Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

iBio has a net margin of 0.00% compared to Upstream Bio's net margin of -5,712.33%. iBio's return on equity of -40.05% beat Upstream Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
iBioN/A -40.05% -35.35%
Upstream Bio -5,712.33%-57.09%-54.69%

iBio has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market. Comparatively, Upstream Bio has a beta of 1.6, meaning that its share price is 60% more volatile than the broader market.

In the previous week, iBio and iBio both had 15 articles in the media. iBio's average media sentiment score of 0.66 beat Upstream Bio's score of 0.27 indicating that iBio is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
iBio
2 Very Positive mention(s)
3 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Upstream Bio
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

iBio beats Upstream Bio on 10 of the 15 factors compared between the two stocks.

How does iBio compare to MediWound?

MediWound (NASDAQ:MDWD) and iBio (NASDAQ:IBIO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

MediWound currently has a consensus price target of $33.00, suggesting a potential upside of 143.54%. iBio has a consensus price target of $6.00, suggesting a potential upside of 749.02%. Given iBio's stronger consensus rating and higher possible upside, analysts plainly believe iBio is more favorable than MediWound.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MediWound
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
iBio
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
2 Strong Buy rating(s)
3.00

MediWound has a beta of 0.07, indicating that its stock price is 93% less volatile than the broader market. Comparatively, iBio has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market.

iBio has a net margin of 0.00% compared to MediWound's net margin of -234.98%. iBio's return on equity of -40.05% beat MediWound's return on equity.

Company Net Margins Return on Equity Return on Assets
MediWound-234.98% -58.44% -29.62%
iBio N/A -40.05%-35.35%

In the previous week, MediWound and MediWound both had 15 articles in the media. iBio's average media sentiment score of 0.66 beat MediWound's score of 0.20 indicating that iBio is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MediWound
1 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral
iBio
2 Very Positive mention(s)
3 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

46.8% of MediWound shares are held by institutional investors. Comparatively, 7.9% of iBio shares are held by institutional investors. 9.2% of MediWound shares are held by company insiders. Comparatively, 1.6% of iBio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

MediWound has higher revenue and earnings than iBio. MediWound is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MediWound$11.86M14.86-$23.88M-$2.21N/A
iBio$100K497.94-$33.04M-$0.28N/A

Summary

iBio beats MediWound on 10 of the 15 factors compared between the two stocks.

How does iBio compare to Keros Therapeutics?

Keros Therapeutics (NASDAQ:KROS) and iBio (NASDAQ:IBIO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk.

Keros Therapeutics presently has a consensus target price of $20.00, indicating a potential upside of 99.40%. iBio has a consensus target price of $6.00, indicating a potential upside of 749.02%. Given iBio's stronger consensus rating and higher probable upside, analysts plainly believe iBio is more favorable than Keros Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Keros Therapeutics
1 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.57
iBio
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
2 Strong Buy rating(s)
3.00

iBio has a net margin of 0.00% compared to Keros Therapeutics' net margin of -256.60%. Keros Therapeutics' return on equity of -21.85% beat iBio's return on equity.

Company Net Margins Return on Equity Return on Assets
Keros Therapeutics-256.60% -21.85% -19.83%
iBio N/A -40.05%-35.35%

In the previous week, Keros Therapeutics had 2 more articles in the media than iBio. MarketBeat recorded 17 mentions for Keros Therapeutics and 15 mentions for iBio. Keros Therapeutics' average media sentiment score of 0.68 beat iBio's score of 0.66 indicating that Keros Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Keros Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
iBio
2 Very Positive mention(s)
3 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Keros Therapeutics has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market. Comparatively, iBio has a beta of 1.48, suggesting that its share price is 48% more volatile than the broader market.

Keros Therapeutics has higher revenue and earnings than iBio. Keros Therapeutics is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Keros Therapeutics$40.76M4.83$87.01M-$2.82N/A
iBio$100K497.94-$33.04M-$0.28N/A

71.6% of Keros Therapeutics shares are owned by institutional investors. Comparatively, 7.9% of iBio shares are owned by institutional investors. 12.6% of Keros Therapeutics shares are owned by company insiders. Comparatively, 1.6% of iBio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

iBio beats Keros Therapeutics on 9 of the 17 factors compared between the two stocks.

Get iBio News Delivered to You Automatically

Sign up to receive the latest news and ratings for IBIO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IBIO vs. The Competition

MetriciBioBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$49.79M$4.07B$7.83B$11.75B
Dividend YieldN/A3.64%2.47%4.41%
P/E Ratio-2.5224.2434.3430.11
Price / Sales497.9414.858.005.32
Price / CashN/A21.8921.0222.34
Price / Book0.464.354.763.85
Net Income-$33.04M-$24.19M$3.52B$393.14M
7 Day Performance-11.11%-7.26%-5.34%-4.53%
1 Month Performance-7.78%-4.96%-3.61%-5.86%
1 Year Performance-39.08%-2.87%0.01%-7.78%

iBio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IBIO
iBio
2.4139 of 5 stars
$0.71
-3.4%
$6.00
+749.0%
-36.9%$49.79M$100KN/A23
CGEN
Compugen
3.4135 of 5 stars
$2.09
flat
$5.00
+139.2%
+28.0%$197.62M$72.76M5.3675
ADCT
ADC Therapeutics
1.9375 of 5 stars
$1.60
+5.6%
$5.00
+213.5%
-66.0%$192.78M$81.36MN/A191
UPB
Upstream Bio
3.357 of 5 stars
$3.20
-5.3%
$26.67
+733.3%
-88.7%$185.13M$2.85MN/A75
MDWD
MediWound
2.3 of 5 stars
$13.82
-2.1%
$33.00
+138.8%
-29.3%$183.57M$16.96MN/A121

Related Companies and Tools


This page (NASDAQ:IBIO) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners